Boehringer chod pap

Physical examination, interview, and blood samples were used to collect information on risk factors. Body mass index (BMI) and body surface area (BSA) were determined using height and weight, and smoking status, as well as antihypertensive and lipid-lowering medicine (statin usage), were evaluated using a questionnaire. Systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg, or current antihypertensive therapy were all considered hypertension. Prediabetes (Impaired fasting glucose: average fasting glucose concentration and a 2-h serum oral glucose tolerance test (OGTT) glucose concentration between 140 and 200 mg/dL; and/or impaired fasting glucose concentration, as defined by fasting glucose levels between 110 and 125 mg/dL and an average 2-h serum glucose concentration), and diabetes (2-h serum glucose concentration as determined by OGTT that was >200 mg/dL and/or a fasting glucose concentration between 110 and 125 mg/dL) were defined according to the WHO criteria [20 ]. At the time of the assessment, all study participants’ venous blood was drawn and sent to the Augsburg Central Hospital laboratory within 2 to 4 h. The Boehringer CHOD-PAP (Roche Diagnostics) test determined total cholesterol. Triglycerides were measured with the Boehringer GPO-PAP assay (non-fasting in diabetic subjects) [10 (link)].

Venous blood was collected from all study participants in fasting state, at examination visit and was shipped within 2 to 4 h to the laboratory of Augsburg Central Hospital. Total cholesterol and LDL cholesterol were measured using the Boehringer CHOD-PAP (Roche Diagnostics GmbH, Mannheim, Germany) assay, and HDL-cholesterol using the phosphotungstic acid method (Boehringer Mannheim, Mannheim, Germany). Triglycerides were measured with the Boehringer GPO-PAP assay (non-fasting in diabetic subjects) [19 (link)].